


RESEARCH

Open Access



Identical tau filaments in subacute sclerosing panencephalitis and chronic traumatic encephalopathy

Chao Qi^{1†}, Masato Hasegawa^{2†}, Masaki Takao^{3,4}, Motoko Sakai⁵, Mayasuki Sasaki⁶, Masashi Mizutani³, Akio Akagi⁷, Yasushi Iwasaki⁷, Hiroaki Miyahara⁷, Mari Yoshida⁷, Sjors H. W. Scheres^{1*} and Michel Goedert^{1*} 

Abstract

Subacute sclerosing panencephalitis (SSPE) occurs in some individuals after measles infection, following a symptom-free period of several years. It resembles chronic traumatic encephalopathy (CTE), which happens after repetitive head impacts or exposure to blast waves, following a symptom-free period. As in CTE, the neurofibrillary changes of SSPE are concentrated in superficial cortical layers. Here we used electron cryo-microscopy (cryo-EM) of tau filaments from two cases of SSPE to show that the tau folds of SSPE and CTE are identical. Two types of filaments were each made of two identical protofilaments with an extra density in the β -helix region. Like in CTE, the vast majority of tau filaments were Type I, with a minority of Type II filaments. These findings suggest that the CTE tau fold can be caused by different environmental insults, which may be linked by inflammatory changes.

Keywords Tau, Subacute sclerosing panencephalitis, Chronic traumatic encephalopathy, Inflammation, Electron cryo-microscopy

Introduction

Subacute sclerosing panencephalitis (SSPE) is a fatal disorder of the central nervous system that occurs following infection with measles virus and manifests itself after a symptom-free period of several years [1]. It occurs in approximately 1 in 75,000 cases of measles [2]. The neuropathology of SSPE is characterized by severe nerve cell loss, demyelination, perivascular lymphocytic infiltrations and viral intranuclear inclusion bodies. By silver staining, abundant neurofibrillary tangles are present in cerebral cortex and other brain regions in a proportion of cases [3, 4]. They have been reported to be made of paired helical filaments like those from Alzheimer's disease brains [5, 6] and stain for abnormally phosphorylated tau and ubiquitin [7]. Tangle-bearing cases of SSPE have mostly a long disease duration [8] and in a recent immunohistochemical study, tau pathology was found in all cases of SSPE [9].

[†]Chao Qi and Masato Hasegawa are contributed equally to this work

*Correspondence:

Sjors H. W. Scheres
scheres@mrc-lmb.cam.ac.uk

Michel Goedert
mg@mrc-lmb.cam.ac.uk

¹ Medical Research Council Laboratory of Molecular Biology, Cambridge, UK

² Department of Brain and Neuroscience, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

³ Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry, Tokyo, Japan

⁴ Department of Neurology and Brain Bank, Mihara Memorial Hospital, Isesaki, Japan

⁵ Department of Neurology, National Hospital Organization Suzuka National Hospital, Suzuka, Mie, Japan

⁶ Department of Child Neurology, Center of Neurology and Psychiatry, Tokyo, Japan

⁷ Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan



Tauopathy has been inferred to result from diffuse brain inflammation triggered by infection with measles virus and not from a direct effect of the virus [9]. Neurofibrillary tangles of SSPE stain with antibodies specific for 3R and 4R tau, like the tau inclusions of primary age-related tauopathy (PART), Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE) [10]. Unlike PART and AD, but like CTE, the neurofibrillary tangles of SSPE are present in superficial cortical layers [9, 11].

We previously used electron cryo-microscopy (cryo-EM) to determine the atomic structures of tau filaments from a number of neurodegenerative conditions, which has resulted in a structure-based classification of tauopathies [12]. We showed that the tau filament folds of 3R + 4R tauopathies separate into two groups, the first of which is formed by PART, AD, and familial British and Danish dementias (FBD and FDD), and the second by CTE. The neurofibrillary pathology associated with some cases of Gerstmann-Sträussler-Scheinker disease (GSS) also belongs to the first group [13]. We now report that the structures of tau filaments from two cases of SSPE are identical to those of CTE. This suggests that the CTE tau fold can form in response to different environmental insults, which may be linked by inflammatory changes.

Materials and methods

Clinical history and neuropathology

We determined the cryo-EM structures of tau filaments from the frontal cortex of two individuals with SSPE. There was no history of head injury. Case 1 was a male who developed measles when 1.5 years old; at age 8, he developed a speech disturbance, as well as eating and walking difficulties. He was diagnosed with SSPE based on clinical presentation, a history of measles infection and characteristic electro-encephalogram and cerebrospinal fluid abnormalities. Despite intensive antiviral treatment, his condition worsened progressively and he died aged 42, after having been on mechanical ventilation for 11 years. The brain was severely atrophic with a weight of 439 g. Neuronal rarefaction was extensive in cerebrum, brainstem and cerebellum and there was a severe loss of myelinated nerve fibres. Tau-immunoreactive NFTs showed a wide distribution and were present in layers II and III of the cerebral cortex. The clinicopathological characteristics of SSPE case 2 have been described [case 4 in [9]]. Briefly, this was a male who developed measles at the age of 0.8 year; at age 22, he developed convulsions, myoclonus and parkinsonism. He was diagnosed with SSPE based on the neurological findings, a history of measles infection, periodic synchronous discharge on electro-encephalogram and cerebrospinal fluid abnormalities. Intensive antiviral treatment failed to improve his symptoms, he became bedridden and died

aged 41. The brain was severely atrophic with a weight of 735 g. Pathological examination revealed the presence of marked brain atrophy with nerve cell loss and gliosis in cerebral cortex, basal ganglia, thalamus and hippocampus, which were associated with severe white matter atrophy [9]. Tau immunoreactive NFTs showed a broad distribution, in particular in superficial layers II and III of the cerebral cortex, in oculomotor nuclei and in the locus coeruleus.

Extraction of tau filaments

Sarkosyl-insoluble material was extracted from the frontal cortex of cases 1 and 2 of SSPE, as described [14], with minor modifications. Briefly, tissues were homogenized with a Polytron in 40 vol (w/v) extraction buffer consisting of 10 mM Tris-HCl, pH 7.4, 0.8 M NaCl, 10% sucrose and 1 mM EGTA. Homogenates were brought to 2% sarkosyl and incubated for 30 min at 37 °C. Following a 10 min centrifugation at 27,000 g, the supernatants were spun at 257,000 g for 30 min. Pellets were resuspended in 2 ml extraction buffer containing 1% sarkosyl and centrifuged at 166,000 g for 20 min. The resulting pellets were resuspended in 100 µl phosphate-buffered saline (PBS) and used for subsequent analyses.

Immunolabelling and histology

Immunogold negative-stain electron microscopy and immunoblotting were carried out as described [15]. For immunoelectron microscopy, the samples were applied onto collodion membrane-applied mesh, blocked with 0.3% gelatin, incubated with AT8 (1:100, Innogenetics 90,206) for 1 h at 37 °C, followed by a 1 h incubation at 37 °C with 10 nm gold-labelled secondary antibody (1:50) and staining with 2% phosphotungstate. For immunoblotting, samples were run on 5–20% gradient gels (Fuji Film). Proteins were then transferred to a polyvinylidene difluoride membrane and incubated with the following primary antibodies overnight at room temperature: Tau N (1:1000, Cosmobio TIP-TAU-P-03), AT8 (1:500), RD3 (1:500, Millipore 05-803), RD4 (1:500, Millipore 05-804), anti-4R (1:1000, BioLegend MMS-5020), Tau354-369 (1:1000, Millipore ABN2178-100UL) and T46 (1:1000, Thermo Fisher Scientific 13-6400). Following washing in PBS, the membranes were incubated with biotinylated anti-mouse or anti-rabbit secondary antibody (Vector, 1:500) for 1 h at room temperature, followed by a 30 min incubation with avidin-biotin complex and colour development using NiCl-enhanced diaminobenzidine as substrate. Histology and immunohistochemistry were carried out as described [16]. Brain sections were 8 µm thick and were counterstained with haematoxylin. Primary antibodies were: RD3 (1:1000); anti-4R (1:1000); AT8 (1:300); anti-measles virus fusion protein antibody




Fig. 1 Frontal cortex from SSPE case 1: Immunohistochemical characterisation of tau inclusions and inflammatory changes. **a** RD3 (specific for 3R tau)-immunoreactive nerve cells and neuropil threads. **b** RD4 (specific for 4R tau)-immunoreactive nerve cells and neuropil threads. **c** AT8 (specific for pS202 and T205 tau)-immunoreactive nerve cells and neuropil threads. **d** Antibody against measles virus shows neuronal staining. **e**, Iba-1-immunoreactive microglial cells. **f** CD3-immunoreactive lymphocytes. Many tau inclusions were found in layers II and III. Scale bars: **a–e**, 50 μ m; **f**, 100 μ m.

(1:1000, Funakoshi bs-0886R); Iba-1 (1:2000, 019-19741); CD3 (1:1000, Novocastra NCL-1-CD3-565).

Electron cryo-microscopy: sample preparation and data collection

Extracted tau filaments were centrifuged at 3000 *g* for 1 min and applied to UltrAuFoil cryo-EM grids [17], which were glow-discharged with an Edwards (S150B) sputter coater at 30 mA for 1 min. Aliquots of 3 μ l were applied to the glow-discharged grids, blotted with filter paper and plunge-frozen into liquid ethane using a

Vitrobot Mark IV (Thermo Fisher Scientific) at 100% humidity and 4 °C. Cryo-EM images were collected on a Titan Krios electron microscope (Thermo Fisher Scientific) operated at 300 kV and equipped with a Falcon-4 direct electron detector. Images were recorded during 6 s exposures in EER (electron event representation) format [18] with a total dose of 40 electrons per Å^2 and a pixel size of 0.824 Å .




Fig. 2 Immunolabelling and immunoblotting of tau filaments from SSPE. **a, b** Immunoelectron microscopy of filaments from SSPE cases 1 (**a**) and 2 (**b**) using anti-tau antibody AT8. **c** Immunoblotting of sarkosyl-insoluble fractions using anti-tau antibodies: Tau N; AT8; RD3; Anti-4R; Tau354; T46. Lanes: 1, SSPE case 1; 2, SSPE case 2; 3, AD

Electron cryo-microscopy: image processing

Image processing was performed using RELION-4.0 [19, 20], unless indicated otherwise. Raw movie frames were gain-corrected, aligned, dose-weighted and summed into a single micrograph. Contrast transfer function (CTF) parameters were estimated using CTFFIND-4.1 [21]. Filaments were picked manually and segments extracted initially with a box size of 1024 pixels. 2D classification was used to remove suboptimal segments and separate Type I from Type II filaments. Selected class averages for Type I and Type II filaments were then re-extracted with a box size of 400 (for SSPE case 1) or 300 (for SSPE case 2) pixels. Initial models were generated de novo from 2D class averages using *relion_helix_inimodel2d* [22]. Helical twist and rise were optimised during 3D auto-refinement. Bayesian polishing and CTF refinement [23] were used to improve the resolution of reconstructions of Type I filaments. Final maps were sharpened using standard post-processing procedures in RELION and their resolutions were calculated based on the Fourier shell correlation (FSC) between two independently refined half-maps at 0.143 [24]. Helical symmetry was imposed on the post-processed maps using the *relion_helix_toolbox* program [25].

Model building and refinement

Atomic models of published CTE filament structures [26] (PDB:6NWP; PDB:6NWQ) were docked manually in the

density using Coot [27]. Model refinements were performed using *Servalcat* [28] and Refmac5 [29, 30]. Models were validated with MolProbity [31]. Figures were prepared with ChimeraX [32] and Pymol [33]. Further details of data acquisition and image processing are given in Additional file 1: Table S1 and Figure S1.

Results

For cryo-EM, we extracted tau filaments from the frontal cortex of two cases of SSPE. Both individuals had measles as children, with the clinical picture of SSPE manifesting itself following a number of symptom-free years.

In SSPE case 1, immunohistochemistry with anti-tau antibodies showed abundant neurofibrillary tangles that were stained by anti-tau antibodies specific for 3R tau, 4R tau and phospho-tau (AT8) (Fig. 1). Neurons and glial cells with intranuclear inclusion bodies were observed using an antibody against measles virus. Microglial cells were activated, as shown by Iba-1 staining; the same was true of cytotoxic and T helper lymphocytes, as evidenced by CD3 staining (Fig. 1). Similar abnormalities have been described in SSPE case 2 [9].

Filaments from the sarkosyl-insoluble fractions were decorated by anti-tau antibodies and gave the same bands on Western blots as those from AD brains (Fig. 2). It has previously been shown that the bands of sarkosyl-insoluble tau from AD are identical to those from CTE [34]. The observed bands indicate that the filaments of SSPE cases 1 and 2 are made of all six tau isoforms in a hyperphosphorylated state, consistent with previous results [9].

By cryo-EM, we show that the CTE fold of assembled tau is characteristic of SSPE cases 1 and 2 (Fig. 3; Additional file 1: Figure S1). As in the CTE fold, two types of tau filaments were present, each with an unknown, internal density in the β -helix of the structured core. Type I and Type II filaments are both made of two identical protofilaments, with different interprotofilament packing, i.e. type I and type II CTE filaments are ultrastructural polymorphs. Type I comprised more than 90% of the observed filaments and Type II less than 10%, similar to what has been observed in CTE [26].

Discussion

SSPE and CTE share a long interval between the primary insult (measles virus infection or repetitive head impacts and blast waves) and the appearance of clinical symptoms. Like AD and CTE, tangle-bearing cases of SSPE are characterised by the presence of abundant filamentous inclusions made of all six brain tau isoforms. Unlike AD, CTE and tangle-bearing cases of SSPE share the formation of abundant tau inclusions in cortical layers II and




Fig. 3 Cryo-EM cross-sections and structures of tau filaments from SSPE. **a** Cross-sections through the cryo-EM reconstructions, perpendicular to the helical thickness and with a projected thickness of approximately one rung, are shown for SSPE cases 1 and 2. A majority of Type I and a minority of Type II tau filaments are each made of two copies of a single protofilament arranged in different ways (ultrastructural polymorphs). Resolutions and filament percentages: SSPE case 1: Type I CTE filament 2.3 Å, 92%; Type II CTE filament 5.1 Å, 8%. SSPE case 2: Type I CTE filament 3.0 Å, 91%; Type II CTE filament 3.5 Å, 9%. Scale bar, 5 nm. **b** Cryo-EM density maps (grey transparent) of SSPE Type I and Type II tau filaments and the atomic models coloured blue (Type I) and orange (Type II). **c** SSPE Type I (blue) and Type II (orange) filaments overlaid with CTE Type I (magenta) and CTE Type II (magenta) filaments. The filament core extends from tau residues K274/S305-R379

III [9, 11]. We previously showed that the CTE fold differs from the Alzheimer tau fold by adopting a more open conformation of the β -helix region, which contains an internal density of unknown identity [26]. In the presence of NaCl, recombinant tau comprising amino acids 297–391 assembles into filaments with the CTE fold, but in its absence, the Alzheimer tau fold forms [35].

We now find that the tau fold of SSPE is identical to that of CTE. As in CTE, two types of filaments, each made of two identical protofilaments, were present in SSPE cases 1 and 2. Western blots of sarkosyl-insoluble tau fractions indicate that these filaments are made of all six (3R+4R) brain tau isoforms [12, 13, 26, 36]. For 3R+4R tauopathies, one protofilament fold (the Alzheimer fold) is found in PART, AD, GSS, FBD and FDD, and

the second protofilament fold (the CTE fold) is found in CTE. The present findings show that SSPE is a second example of a 3R+4R tauopathy with the CTE fold. It remains to be seen if other conditions with tau inclusions in cortical layers II and III also share the CTE fold.

Inflammation may be what CTE and SSPE have in common. In SSPE case 2, extensive inflammatory changes have been described, with perivascular lymphocyte infiltration, aggregates of hypertrophic astrocytes and activated microglia [9]. Here we show that the frontal cortex from SSPE case 1 also exhibited microglial activation and lymphocyte infiltration. Immunoreactivity for measles virus was present in both cases of SSPE, even though they had undergone antiviral treatment. In untreated cases of long disease duration,

measles virus was detected in cases with neurofibrillary lesions [37]. In treated cases, the detection frequency of measles virus was decreased, even though neurofibrillary pathology was unaffected, suggesting that antiviral therapies may not be able to suppress the progression of tauopathy following SSPE [9]. It remains to be seen if tau inclusions influence the clinical picture of SSPE. Inflammatory changes also occur in CTE, where microglial cell activation is believed to increase tau pathology and the presence of abundant CD68-positive microglial cells has been demonstrated [38]. Moreover, translocator protein (TSPO) positron emission tomography ligands for activated microglia have shown increased signal in retired American football players who are at risk for CTE [39].

It is unclear how inflammation and microglial cell activation affect tau assembly. Microglial cell activation has been reported to promote tau assembly in mice [40–42] and it also characterizes neurodegenerative diseases with filamentous tau pathology other than SSPE and CTE, the most studied of which is AD [43, 44]. More work is required to identify the links between neuroinflammation and tau assembly.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40478-023-01565-2>.

Additional file 1. Supplementary information: Table S1 and Figure S1.

Acknowledgements

This work was supported by the Electron Microscopy Facility of the MRC Laboratory of Molecular Biology. We thank Jake Grimmett, Toby Darling and Ivan Clayson for help with high-performance computing. We also thank Ms R. Otani for technical assistance and Professor B. Ghetti for helpful discussions. For the purpose of open access, the MRC Laboratory of Molecular Biology has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising.

Author contributions

MH, MT, MS, AA, YI, HM and MY identified the patients and performed neuropathology; MH extracted filaments and performed immunoelectron microscopy and Western blotting; CQ performed cryo-EM data acquisition and structure determination; SHWS and MG supervised the project and all authors contributed to the writing of the manuscript.

Funding

This work was funded by the Medical Research Council, as part of UK Research and Innovation (MC-UP-A025-1013 to S.H.W.S. and MC-U105184291 to M.G.). It was also supported by the Japan Agency for Science and Technology (Crest, JPMJCR18H3, to M.H.) and the Japan Agency for Medical Research and Development (AMED, JP20dm0207072, to M.H., and AMED, JP21wm0425019, to M.T.). M.T. was supported by intramural funds from the National Center of Neurology and Psychiatry.

Availability of data and materials

Cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB) with the accession numbers EMD-16532, EMD-16535. Corresponding refined atomic models have been deposited in the Protein Data Bank (PDB) under accession numbers 8CAQ, 8CAX. Please address requests for materials to the corresponding authors.

Declarations

Competing Interests

The authors declare that they have no competing interests.

Received: 2 February 2023 Accepted: 10 April 2023

Published online: 05 May 2023

References

- Dawson JR (1934) Cellular inclusions in cerebral lesions of epidemic encephalitis. *Arch Neurol Psychiat* 31:685–700
- Okuno Y, Nakao T, Ishida N, Konno T, Mizutani H, Fukuyama Y, Sato T, Isomura S, Ueda S, Kitamura I et al (1989) Incidence of subacute sclerosing panencephalitis following measles and measles vaccination in Japan. *Int J Epidemiol* 18:684–689
- Corsellis JAN (1951) Sub-acute sclerosing leuco-encephalitis: a clinical and pathological report of two cases. *J Mental Sci* 97:570–583
- Malamud N, Haymaker W, Pinkerton H (1950) Inclusion encephalitis. With a clinicopathologic report of two cases. *Am J Pathol* 26:133–150
- Mandybur TI, Nagpaul AS, Pappas Z, Niklowitz WJ (1977) Alzheimer neurofibrillary change in subacute sclerosing panencephalitis. *Ann Neurol* 1:103–107
- Paula-Barbosa MM, Brito R, Silva CA, Faria R, Cruz C (1979) Neurofibrillary changes in the cerebral cortex of a patient with subacute sclerosing panencephalitis. *Acta Neuropathol* 48:157–160
- Wisniewski HM, Dymecki J, Wegiel J, Kulczycki J, Schmidt-Sidor B, Grundke-Iqbal I, Strojny P (1991) Neurofibrillary pathology in subacute sclerosing panencephalitis. *Dementia* 2:133–141
- Bancher C, Leitner H, Jellinger K, Eder H, Setinek U, Fischer P, Wegiel J, Wisniewski HM (1996) On the relationship between measles virus and Alzheimer neurofibrillary tangles in subacute sclerosing panencephalitis. *Neurobiol Aging* 17:527–533
- Miyahara H, Akagi A, Riku Y, Sone J, Otsuka Y, Sakai M, Kuru S, Hasegawa M, Yoshida M, Kakita A et al (2022) Independent distribution between tauopathy secondary to subacute sclerosing panencephalitis and measles virus. *Brain Pathol* 32:e13069
- Goedert M, Eisenberg DS, Crowther RA (2017) Propagation of tau aggregates and neurodegeneration. *Annu Rev Neurosci* 40:189–210
- Hof PR, Bouras C, Buée L, Delacourte A, Perl DP, Morrison JH (1992) Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. *Acta Neuropathol* 85:23–30
- Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ et al (2021) Structure-based classification of tauopathies. *Nature* 598:359–363
- Hallinan GI, Hoq MR, Ghosh M, Vago FS, Fernandez A, Garringer HJ, Vidal R, Jiang W, Ghetti B (2021) Structure of Tau filaments in prion protein amyloidosis. *Acta Neuropathol* 142:227–241
- Tarutani A, Arai T, Murayama S, Hisanaga SI, Hasegawa M (2018) Potent prion-like behaviors of pathogenic α -synuclein and evaluation of inactivation methods. *Acta Neuropathol Commun* 6:29
- Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. *Neuron* 8:159–168
- Spina S, Falcon MR, Unverzagt FW, Kareken DA, Murrell JR, Fraser G, Epperson F, Crowther RA, Spillantini MG, Goedert M et al (2008) The tauopathy associated with mutation +3 of intron 10 in *Tau*: characterization of the MSTD family. *Brain* 131:72–89
- Russo CJ, Passmore LA (2014) Electron microscopy: ultrastable gold substrates for electron cryo-microscopy. *Science* 346:1377–1380
- Guo H, Franken E, Deng Y, Benlekhir S, Lezcano GS, Janssen B, Yu L, Ripstein ZA, Tan YZ, Rubinstein JL (2020) Electron-event representation data enable efficient cryoEM file storage with full preservation of spatial and temporal resolution. *IUCr* 7:860–869
- Scheres SHW (2012) A Bayesian view on cryo-EM structure determination. *J Mol Biol* 415:406–418

20. Kimanius D, Dong L, Sharov G, Nakane T, Scheres SHW (2021) New tools for automated cryo-EM single-particle analysis in RELION-4.0. *Biochem J* 478:4169–4185
21. Rohou A, Grigorieff N (2015) CTFIND4: fast and accurate defocus estimation from electron micrographs. *J Struct Biol* 192:216–221
22. Scheres SHW (2020) Amyloid structure determination in RELION-3.1. *Acta Cryst D* 76:94–101
23. Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, Scheres SHW (2018) New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* 7:e42166
24. Scheres SHW, Chen S (2012) Prevention of overfitting in cryo-EM structure determination. *Nature Meth* 9:8453–8854
25. He S, Scheres SHW (2017) Helical reconstruction in RELION. *J Struct Biol* 193:163–176
26. Falcon B, Zivanov J, Zhang W, Murzin AG, Garringer HJ, Vidal R, Crowther RA, Newell KL, Ghetti B, Goedert M et al (2019) Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. *Nature* 568:420–423
27. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. *Acta Crystallogr D* 66:486–501
28. Yamashita K, Palmer CM, Burnley T, Murshudov GN (2021) Cryo-EM single-particle structure refinement and map calculation using *Servalcat*. *Acta Crystallogr D* 77:1282–1291
29. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D* 53:240–255
30. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA (2011) REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D* 67:355–267
31. Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kaprai GJ, Murray LW, Richardson JS, Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D* 66:12–21
32. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE (2021) ChimeraX: structure visualization for researchers, educators, and developers. *Protein Sci* 30:70–82
33. Schrödinger L, DeLano W (2020) PyMOL. available at: <http://www.pymol.org/pymol>
34. Schmidt ML, Zhukareva V, Newell KL, Lee VMY, Trojanowski JQ (2001) Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease. *Acta Neuropathol* 101:518–524
35. Lövestam S, Koh FA, van Knippenberg B, Kotecha A, Murzin AG, Goedert M, Scheres SHW (2022) Assembly of recombinant tau into filaments like those of Alzheimer's disease and chronic traumatic encephalopathy. *Elife* 11:e76494
36. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. *Nature* 547:185–190
37. McQuaid S, Allen IV, McMahon J, Kirk J (1994) Association of measles virus with neurofibrillary tangles in subacute sclerosing panencephalitis: a combined *in situ* hybridization and immunocytochemical investigation. *Neuropathol Appl Neurobiol* 20:103–110
38. Cherry JD, Tripodis Y, Alvarez VE, Huber B, Kiernan PT, Daneshvar DH, Mez J, Montenigro PH, Solomon TM, Alosco ML et al (2016) Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. *Acta Neuropathol Commun* 4:112
39. Coughlin JM, Wang Y, Munro CA, Ma S, Yue C, Chen S, Airan R, Kim PK, Adams AV, Garcia C et al (2015) Neuroinflammation and brain atrophy in former NFL players: an *in vivo* multimodal imaging pilot study. *Neurobiol Dis* 74:58–65
40. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. *Am J Pathol* 167:1643–1652
41. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhars T, Trojanowski JQ, Lee VMY (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron* 53:337–351
42. Maphis N, Xu G, Kokiko-Cochran ON, Jiang S, Cardona A, Ransohoff RM, Lamb BT, Bhaskar K (2015) Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. *Brain* 138:1738–1755
43. Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szrenfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S et al (2017) A unique microglia type associated with restricting development of Alzheimer's disease. *Cell* 169:1276–2190
44. McGeer PL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. *Neurosci Lett* 79:195–200

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

